AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Create a link to this page

Copy and paste this link tag into your Web page or blog:

<a href="http://www.accessmylibrary.com/coms2/summary_0286-12486577_ITM" title="Facts and information about New Licensing Agreement to Maximize AIDS Drug Development.">New Licensing Agreement to Maximize AIDS Drug Development.</a>

Close Set up an RSS feed that alerts you when new articles from PR Newswire are available.

Frequently asked questions about RSS feeds

New Licensing Agreement to Maximize AIDS Drug Development.

PR Newswire

| February 01, 2006 | COPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

CONRAD and Cellegy Pharmaceuticals Formalize Collaboration of Microbicide R&D

ARLINGTON, Va., Feb. 1 /PRNewswire/ -- Longtime collaborators CONRAD and the Biosyn Division of Cellegy Pharmaceuticals, Inc. today announced a non- exclusive licensing agreement to research and develop Biosyn-patented microbicides for the prevention of HIV and other sexually transmitted diseases.

The three microbicides covered under the agreement are in various stages of development and work under different mechanisms of action. They include: Savvy, which is currently in Phase III clinical trials in the U.S. and Africa; UC781 which is in expanded Phase II trials in the U.S. and…

View articles courtesy of your local library

Related articles from newspapers, magazines, journals, and more


Cellegy Pharmaceuticals Conference Call: Sale of Assets to ProStrakan - Final.: News wire article from: Fair Disclosure Wire September 27, 2006 700+ words
...Gentlemen, and welcome to the Cellegy Pharmaceuticals sale of assets to ProStrakan...CHAIRMAN, INTERIM CEO, CELLEGY PHARMACEUTICALS: Thank you. Good morning...shifted the Savvy workforce to Conrad and other infrastructure...


Cellegy Pharmaceuticals Reports First Quarter Financial Results: Press release article from: PR Newswire May 1, 1998 700+ words
...Calif., May 1 /PRNewswire/ -- Cellegy Pharmaceuticals, Inc. (Nasdaq: CLGY) today...plans in the coming months." Cellegy Pharmaceuticals is engaged in the development...year ended December 31, 1997. CELLEGY PHARMACEUTICALS, INC. Summary Financial Results...


Cellegy Pharmaceuticals receives FDA non-approvable letter for Fortigel.: News wire article from: Asia Africa Intelligence Wire July 7, 2003 700+ words
...Business NewsBase - Press Release) Cellegy Pharmaceuticals Inc has received a communication...gel) 2% is not approvable. Cellegy Pharmaceuticals plans to meet with the Agency...class effect." Results of Cellegy Pharmaceuticals' clinical trials provide evidence...


Cellegy Pharmaceuticals Second Quarter 2003 Conference Call & Business Update.: Press release article from: PR Newswire August 11, 2003 700+ words
Cellegy Pharmaceuticals Inc. , will release 2003 second quarter results...and entering reservation number 2143023. About Cellegy Pharmaceuticals Inc. Cellegy Pharmaceuticals is a specialty biopharmaceutical company engaged...


Cellegy Pharmaceuticals Reports Fiscal 1997 Financial Results: Press release article from: PR Newswire April 1, 1998 700+ words
...Calif., April 1 /PRNewswire -- Cellegy Pharmaceuticals, Inc. (Nasdaq: CLGY) today...towards commercialization." Cellegy Pharmaceuticals is engaged in the development...year ended December 31, 1997. CELLEGY PHARMACEUTICALS, INC. SUMMARY FINANCIAL RESULTS...


Cellegy Pharmaceuticals Initiates Clinical Trial Enrollment for Anogesic(R): Press release article from: PR Newswire July 22, 1998 700+ words
...July 22 /PRNewswire/ -- Cellegy Pharmaceuticals, Inc. (Nasdaq: CLGY) announced...schedule for nitroglycerin use." Cellegy Pharmaceuticals, Inc. is a bio-pharmaceutical...development by Cellegy. SOURCE Cellegy Pharmaceuticals, Inc. -0- 07/22/98 /CONTACT...


Research and Markets: The Cellegy Pharmaceuticals Inc Competitor Report...: Press release article from: Business Wire January 29, 2007 700+ words
...announced the addition of "Cellegy Pharmaceuticals Inc - Competitor Report" to their offering. The Cellegy Pharmaceuticals Inc Competitor Report...information available. The Cellegy Pharmaceuticals Inc Competitor report...


Cellegy Pharmaceuticals Reports Third Quarter Financial Results.: Press release article from: Business Wire October 16, 1997 700+ words
...HealthWire)--Oct. 16, 1997--Cellegy Pharmaceuticals Inc. (NASDAQ:CLGY) Thursday...technology from the company. Cellegy Pharmaceuticals is engaged in the development...ended Dec. 31, 1996. -0- Cellegy Pharmaceuticals Inc. Summary Financial Results...


Cellegy Pharmaceuticals Receives FDA Non Approvable Letter for Fortigel;...: Press release article from: PR Newswire July 7, 2003 700+ words
Cellegy Pharmaceuticals, Inc. announced today that it has received...International): 706-634-2467 Reference: Cellegy Pharmaceuticals, Inc. About Cellegy Pharmaceuticals: Cellegy Pharmaceuticals is a specialty biopharmaceutical...


Cellegy Pharmaceuticals Acquires Additional Patent Rights to Nitric Oxide Donor...: Press release article from: PR Newswire June 5, 2003 700+ words
Cellegy Pharmaceuticals, Inc. announced today...in the United States." Cellegy Pharmaceuticals is a specialty biopharmaceutical...President & CEO, both of Cellegy Pharmaceuticals, +1-650-616-2200...

For more facts and information, see all results

Source: HighBeam Research, New Licensing Agreement to Maximize AIDS Drug Development.

The AccessMyLibrary advertising network includes: